vs

Side-by-side financial comparison of BioAge Labs, Inc. (BIOA) and KOSS CORP (KOSS). Click either name above to swap in a different company.

BioAge Labs, Inc. is the larger business by last-quarter revenue ($3.1M vs $2.9M, roughly 1.1× KOSS CORP). KOSS CORP runs the higher net margin — -19.8% vs -842.9%, a 823.1% gap on every dollar of revenue. KOSS CORP produced more free cash flow last quarter ($-1.1M vs $-28.4M).

Altos Labs, Inc. is an American biotechnology research company. Altos Labs' goal is to develop life extension therapies that can halt or reverse the human aging process. Specialized cell therapies based on induced pluripotent stem cells are to be developed for this purpose. Russian-born technology businessman Yuri Milner, along with investors including Jeff Bezos, funded the company in 2021, operations started in 2022.

Koss Corporation is a company in Milwaukee, Wisconsin, US that manufactures headphones. The company created the first high-fidelity stereo headphones in 1958.

BIOA vs KOSS — Head-to-Head

Bigger by revenue
BIOA
BIOA
1.1× larger
BIOA
$3.1M
$2.9M
KOSS
Higher net margin
KOSS
KOSS
823.1% more per $
KOSS
-19.8%
-842.9%
BIOA
More free cash flow
KOSS
KOSS
$27.3M more FCF
KOSS
$-1.1M
$-28.4M
BIOA

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
BIOA
BIOA
KOSS
KOSS
Revenue
$3.1M
$2.9M
Net Profit
$-25.9M
$-565.4K
Gross Margin
29.0%
Operating Margin
-923.4%
-35.5%
Net Margin
-842.9%
-19.8%
Revenue YoY
-19.6%
Net Profit YoY
-700.6%
EPS (diluted)
$-0.72
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOA
BIOA
KOSS
KOSS
Q4 25
$3.1M
$2.9M
Q3 25
$2.1M
$4.1M
Q2 25
$2.4M
$3.1M
Q1 25
$1.5M
$2.8M
Q4 24
$3.6M
Q3 24
$0
$3.2M
Q2 24
$2.9M
Q1 24
$2.6M
Net Profit
BIOA
BIOA
KOSS
KOSS
Q4 25
$-25.9M
$-565.4K
Q3 25
$-20.2M
$243.7K
Q2 25
$-21.6M
$-232.7K
Q1 25
$-12.9M
$-316.7K
Q4 24
$94.1K
Q3 24
$-23.4M
$-419.5K
Q2 24
$-110.4K
Q1 24
$-313.8K
Gross Margin
BIOA
BIOA
KOSS
KOSS
Q4 25
29.0%
Q3 25
40.0%
Q2 25
36.0%
Q1 25
39.0%
Q4 24
39.5%
Q3 24
36.6%
Q2 24
40.4%
Q1 24
31.9%
Operating Margin
BIOA
BIOA
KOSS
KOSS
Q4 25
-923.4%
-35.5%
Q3 25
-1126.6%
-1.1%
Q2 25
-1027.0%
-14.2%
Q1 25
-1133.4%
-18.7%
Q4 24
-4.0%
Q3 24
-19.9%
Q2 24
-11.0%
Q1 24
-23.1%
Net Margin
BIOA
BIOA
KOSS
KOSS
Q4 25
-842.9%
-19.8%
Q3 25
-982.0%
6.0%
Q2 25
-894.0%
-7.5%
Q1 25
-891.0%
-11.4%
Q4 24
2.6%
Q3 24
-13.1%
Q2 24
-3.8%
Q1 24
-11.9%
EPS (diluted)
BIOA
BIOA
KOSS
KOSS
Q4 25
$-0.72
$-0.06
Q3 25
$-0.56
$0.03
Q2 25
$-0.60
$-0.02
Q1 25
$-0.36
$-0.03
Q4 24
$0.01
Q3 24
$-6.70
$-0.05
Q2 24
$-0.01
Q1 24
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOA
BIOA
KOSS
KOSS
Cash + ST InvestmentsLiquidity on hand
$281.1M
$15.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$272.1M
$30.3M
Total Assets
$294.9M
$36.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOA
BIOA
KOSS
KOSS
Q4 25
$281.1M
$15.5M
Q3 25
$285.8M
$16.5M
Q2 25
$297.3M
$15.7M
Q1 25
$320.5M
$13.0M
Q4 24
$9.7M
Q3 24
$334.5M
$11.9M
Q2 24
$14.9M
Q1 24
$9.9M
Total Debt
BIOA
BIOA
KOSS
KOSS
Q4 25
Q3 25
Q2 25
Q1 25
$7.1M
Q4 24
Q3 24
$9.9M
Q2 24
Q1 24
Stockholders' Equity
BIOA
BIOA
KOSS
KOSS
Q4 25
$272.1M
$30.3M
Q3 25
$277.5M
$30.9M
Q2 25
$294.8M
$30.6M
Q1 25
$313.2M
$30.7M
Q4 24
$31.0M
Q3 24
$313.7M
$30.8M
Q2 24
$31.1M
Q1 24
$31.1M
Total Assets
BIOA
BIOA
KOSS
KOSS
Q4 25
$294.9M
$36.8M
Q3 25
$305.1M
$37.7M
Q2 25
$322.1M
$37.2M
Q1 25
$343.8M
$37.3M
Q4 24
$37.4M
Q3 24
$337.4M
$38.1M
Q2 24
$37.2M
Q1 24
$37.6M
Debt / Equity
BIOA
BIOA
KOSS
KOSS
Q4 25
Q3 25
Q2 25
Q1 25
0.02×
Q4 24
Q3 24
0.03×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOA
BIOA
KOSS
KOSS
Operating Cash FlowLast quarter
$-28.3M
$-760.8K
Free Cash FlowOCF − Capex
$-28.4M
$-1.1M
FCF MarginFCF / Revenue
-921.5%
-37.5%
Capex IntensityCapex / Revenue
3.6%
10.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-82.3M
$-546.7K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOA
BIOA
KOSS
KOSS
Q4 25
$-28.3M
$-760.8K
Q3 25
$-16.0M
$762.6K
Q2 25
$-20.0M
$-534.9K
Q1 25
$-17.4M
$370.4K
Q4 24
$-252.0K
Q3 24
$201.6K
Q2 24
$-174.0K
Q1 24
$328.6K
Free Cash Flow
BIOA
BIOA
KOSS
KOSS
Q4 25
$-28.4M
$-1.1M
Q3 25
$-16.1M
$761.5K
Q2 25
$-20.1M
$-541.8K
Q1 25
$-17.8M
$306.2K
Q4 24
$-314.3K
Q3 24
$-155.6K
Q2 24
$-174.8K
Q1 24
$269.3K
FCF Margin
BIOA
BIOA
KOSS
KOSS
Q4 25
-921.5%
-37.5%
Q3 25
-782.2%
18.7%
Q2 25
-834.5%
-17.6%
Q1 25
-1226.0%
11.0%
Q4 24
-8.8%
Q3 24
-4.9%
Q2 24
-6.0%
Q1 24
10.2%
Capex Intensity
BIOA
BIOA
KOSS
KOSS
Q4 25
3.6%
10.9%
Q3 25
1.1%
0.0%
Q2 25
6.6%
0.2%
Q1 25
29.4%
2.3%
Q4 24
1.8%
Q3 24
11.2%
Q2 24
0.0%
Q1 24
2.3%
Cash Conversion
BIOA
BIOA
KOSS
KOSS
Q4 25
Q3 25
3.13×
Q2 25
Q1 25
Q4 24
-2.68×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons